Pharmaceutical company is commencing recruitment for exploratory Ph I trial of the active IMP in healthy volunteers in relation to COVID-19

The company MedinCell S.A is recruting for the clinical trial of the Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19.

This is an early stage trial to check how safe and tolerable, as well as how the body handles continuous daily use of Active IMP over 28 days in healthy volunteers to help with coronavirus infection (COVID-19).

Volunteers must meet the following criteria:

• Negative reverse transcription polymerase chain reaction (RT-PCR) Test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) at Screening and negative lateral flow immunoassay test for SARS-CoV-2 at Day -1.
• Healthy as determined by a responsible physician, based on medical evaluation including medical history, physical examinations, neurological examinations, concomitant medication, vital signs, 12-lead ECG and clinical laboratory evaluations.

 and others.

Pharmacokinetic concentrations is the primary outcome measure.

MAC Clinical Research is the collaborator in this clinical trial.

MedinCell is a pharmaceutical company that has created technology for drug delivery by subcutaneous injection that allows treatment adherence.

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT04632706..